Exelixis Stock Soars on Promising Colorectal Cancer Drug Trial Results
Exelixis Inc.’s stock price has surged following promising trial results for its colorectal cancer drug, zanzalintinib, with analysts predicting significant future growth and sales potential.
2 minutes to read